香港股市 已收市

Metacrine, Inc. (MTCR)

NasdaqCM - NasdaqCM 延遲價格。貨幣為 USD。
加入追蹤清單
0.4853-0.0149 (-2.98%)
收市價: 03:27PM EDT
0.4851 -0.00 (-0.04%)
收市後: 06:14PM EDT
全螢幕
交易股價資料並非來自所有市場
前收市價0.5002
開市0.5010
買盤0.4851 x 1000
賣出價0.4948 x 800
今日波幅0.4810 - 0.5011
52 週波幅0.3500 - 4.1200
成交量292,243
平均成交量383,377
市值20.659M
Beta 值 (5 年,每月)
市盈率 (最近 12 個月)
每股盈利 (最近 12 個月)-1.9320
業績公佈日2022年11月09日 - 2022年11月14日
遠期股息及收益率無 (無)
除息日
1 年預測目標價0.50
  • Benzinga

    Metacrine To Slash Its Workforce By 50%

    Metacrine Inc (NASDAQ: MTCR) will ax half of its staff to conserve cash as it makes a last-stand drug development effort. Its shares are mired deep in penny stock territory after it floated its IPO in 2020 at $13/share. While NASH was originally Metacrine's priority, the Company abandoned the program back in October after a toxicology study flagged potential delay. Instead, it pushed their FXR agonist, MET642, into a Phase 2 trial for inflammatory bowel disease. Metacrine announced its reorganiz

  • Benzinga

    Metacrine Posts Data From MET409 Combination Trial In Diabetes, NASH Patients

    Metacrine Inc (NASDAQ: MTCR) reported topline results from its Phase 2a trial of MET409 in combination with Eli Lilly And Co's (NYSE: LLY) Jardiance (empagliflozin) in type 2 diabetes and non-alcoholic steatohepatitis (NASH). LDL-cholesterol increases with MET409 were consistent with previous studies and were comparable alone or in combination with empagliflozin. Secondary assessment of liver fat content at 12 weeks indicated a reduction in liver fat in both monotherapy arms and demonstrated add

  • Benzinga

    How The Future Looks For Last Week's Biggest Losers: Vinco Ventures, Atea Pharmaceuticals And More

    Last week, the five biggest stock market losers declined between about 75% and 37%. Below is a look at each stock and what they may have in the cards going forward. Galera Therapeutics, Inc (NASDAQ: GRTX) gapped down about 70% lower on Tuesday of last week, making it the biggest loser in the stock market. Although big bullish volume came in immediately following the drop, the stock was unable to erase much of its losses and closed the trading day up just 8% higher. Galera is now trading in a con